ClinicalTrials.gg
CompletedNCT01292603Updated Dec 19, 2018Results posted

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

A Phase 1 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 84 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
13th of 145
240 · median 49
Started
2011
with 7 others
Phase 1
22 of 155
1 open now
Registered
113th of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 13th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 22 in phase 1, and was the 113th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This randomized, parallel-group, multi-center study will compare the pharmacokinetics and safety of subcutaneous administration of MabThera (rituximab) versus intravenous MabThera in combination with chemotherapy in previously untreated patients with chronic lymphocytic leukemia (CLL). The study consists of 2 parts. In part 1, patients who have previously received 4 cycles of intravenous MabThera will receive in Cycle 5 intravenous MabThera and in Cycle 6 subcutaneous MabThera. In part 2, patients will be randomized to receive either 6 cycles of intravenous MabThera, or 1 cycle of intravenous MabThera and 5 cycles of subcutaneous MabThera. Additionally, all patients will receive chemotherapy (fludarabine and cyclophosphamide) on Days 1-3 or Days 1-5 of every cycle. The anticipated time on study drug is 24 weeks.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/=18 years of age
  • Patients with treatment-requiring chronic lymphocytic leukemia (CLL)
  • (ECOG) performance status of 0-1
  • >6 months

Exclusion criteria

Exclusion Criteria:

  • Transformation to aggressive B-cell
  • History of other malignancy unless the patient was treated with curative intent and has been in remission for more than 5 years prior to enrolment
  • or positive unless clearly due to vaccination
  • Inadequate liver or renal function
  • Any coexisting medical or psychological condition that would preclude participation in the required study procedures

Additional exclusion criterion for Part 1:

  • Any previous treatment for CLL except for up to 4 cycles of rituximab IV in combination with FC chemotherapy as treatment for CLL

Additional exclusion criterion for Part 2:

  • Any previous treatment for CLL
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    1

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]

  • Experimental
    2

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]

  • Experimental
    3

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rituximab [MabThera]

Interventions

  • Days 1-3 or Days 1-5 of cycles 1-6

  • Days 1-3 or Days 1-5 of cycles 1-6

  • One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera

  • After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.

  • 6 cycles of intravenous MabThera

06

What researchers measure

Primary outcomes

  1. Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab

    Ctrough is defined as the trough or minimum serum concentration. Pharmacokinetic parameters for rituximab were assessed during Cycles 5 (IV rituximab) and 6 (SC rituximab). Rituximab pharmacokinetic (PK) data from Part 1 were integrated into a population PK model using parametric, nonlinear, mixed-effects modelling. Rituximab IV 500 mg/m\^2 administered once every 4 weeks was compared to fixed doses of rituximab SC between 1400 mg and 1870 mg. The dose selection was performed on Ctrough concentrations at Cycle 5 (pre-dose Cycle 6). A test of the probability of success was applied to each of the 100 replicates, and the percentage of replicates with a positive test corresponded to the probability of success of the trial.

    Time frame: Pre-dose and post-dose (15 minutes to end of infusion) on Day 1 and on Days 2, 5, 11 and 15 of Cycle 5 and Pre-dose, Post-dose on Days 2, 3, 5,11, 15 and 29 of Cycle 6; Pre-dose was taken 2 hours prior rituximab dose

  2. Part 2: Rituximab C Trough Levels at Cycle 5

    Ctrough is defined as the trough or minimum serum concentration in a given cycle of treatment. The objective of Part 2 was to demonstrate the comparability of the observed Ctrough of rituximab SC 1600 mg and rituximab IV 500 mg/m2 at Cycle 5, as assessed by a non-inferiority test with a lower boundary of at least 0.8 for the 90% CI.

    Time frame: +/- 25hours around the 28th day post the 5th Cycle of Rituximab administration

Secondary outcomes

  1. Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6

    AUC values were calculated by numerical integration using the linear trapezoidal rule. AUC levels were analyzed using the model below: Ln(AUC) = μ + τi + BlTLij + εij wherein, Ln is the natural log, μ denotes the overall mean effect, τi the effect in each treatment group, BlTLij the tumor load at baseline for each patient and εij a random error variable with normal distribution and mean 0. The treatment effect therein was based on a contrast statement in the model to calculate 90 % confidence intervals for ln(AUC SC)- ln(AUC IV).

    Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6

  2. Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6

    Cmax was obtained directly from the measured concentration-time curves. The concentration-time curve is the result of time points of blood sampling and its measured concentration of rituximab in the blood samplings.

    Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6

  3. Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6

    Multiple blood samples were obtained at pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab IV arm, and at pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab SC arm and time to peak plasma concentration of rituximab was determined.

    Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6

  4. Part 2: Terminal Half-Life of Rituximab at Cycle 6

    The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.

    Time frame: Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6

  5. Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration

    In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC

    Time frame: Days 4 to 5 in Cycle 6

  6. Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV

    Physicians and nurses who administered rituximab were asked to answer the following question: " If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones)". The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.

    Time frame: Days 4-5 in Cycle 6

  7. Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV

    Physicians and nurses who administered rituximab were asked to answer the following question: "Which formulation of rituximab (SC or IV) do you think is more convenient?" with pre-specified responses as below. Percentage of participants with specified answers were reported. The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.

    Time frame: Days 4-5 in Cycle 6

  8. Part 1: Percentage of Participants With Anti-Rituximab Antibodies

    Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.

    Time frame: Predose at Cycles 5 and 6 and at each follow up visit until 24 months after the last dose

  9. Part 2: Percentage of Participants With Anti-Rituximab Antibodies

    In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.

    Time frame: Day 0 of Cycle 1 and Day 1 of Cycles 1, 2, 3, 4, 5, and 6 and at each follow-up visit until 24 months after the last dose of rituximab.

  10. Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit

    CD 19 is a surface antigen (protein) present on B-lymphocytes.

    Time frame: Day 1 of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15,18, 21 and 24

  11. Part 1: Percentage of Participants With Total B-Cell Depletion by Visit

    Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.

    Time frame: Day 1 pre-dose of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15, 18, 21 and 24

  12. Part 2: Total CD19+ B-Cell Counts by Visit

    CD 19 is a surface antigen (protein) present on B-lymphocytes.

    Time frame: Cycle 1 pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 pre-dose in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit

  13. Part 2: Percentage of Participants With Total B-Cell Depletion by Visit

    Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.

    Time frame: Cycle 1 Pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit

07

Results

Posted Dec 15, 2015

Participant flow

Part 1: Pilot Dose Selection Period
Participant flow — Part 1: Pilot Dose Selection Period
MilestonePart 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Started161723800
Completed161723000
Not completed000800
Withdrew: Adverse event000400
Withdrew: Death000100
Withdrew: Protocol violation000200
Withdrew: Withdrawal by subject000100
Part 1: Regular Follow-Up Period
Participant flow — Part 1: Regular Follow-Up Period
MilestonePart 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Started161723800
Completed101017700
Not completed676100
Withdrew: Death313100
Withdrew: Disease progression363000
Part 2: Dose Confirmation Period
Participant flow — Part 2: Dose Confirmation Period
MilestonePart 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Started00008888
Completed00007273
Not completed00001615
Withdrew: Death000010
Withdrew: Physician decision000020
Withdrew: Withdrawn prior to treatment000011
Withdrew: Adverse event000079
Withdrew: Protocol violation000053
Withdrew: Withdrawal by subject000002
Part 2: Regular Follow-Up
Participant flow — Part 2: Regular Follow-Up
MilestonePart 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Started00008787
Completed00006875
Not completed00001912
Withdrew: Death000063
Withdrew: Disease progression000055
Withdrew: Noncompliance000010
Withdrew: Withdrawal by subject000001
Withdrew: Protocol violation000020
Withdrew: Physician decision000020
Withdrew: Lost to follow-up000011
Withdrew: Adverse event000022
Overall Survival Status
Participant flow — Overall Survival Status
MilestonePart 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Started16172388888
Completed13162077278
Not completed31311610
Withdrew: Death31311610

Outcome measures

PrimaryPart 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab

Ctrough is defined as the trough or minimum serum concentration. Pharmacokinetic parameters for rituximab were assessed during Cycles 5 (IV rituximab) and 6 (SC rituximab). Rituximab pharmacokinetic (PK) data from Part 1 were integrated into a population PK model using parametric, nonlinear, mixed-effects modelling. Rituximab IV 500 mg/m\^2 administered once every 4 weeks was compared to fixed doses of rituximab SC between 1400 mg and 1870 mg. The dose selection was performed on Ctrough concentrations at Cycle 5 (pre-dose Cycle 6). A test of the probability of success was applied to each of the 100 replicates, and the percentage of replicates with a positive test corresponded to the probability of success of the trial.

Time frame:
Pre-dose and post-dose (15 minutes to end of infusion) on Day 1 and on Days 2, 5, 11 and 15 of Cycle 5 and Pre-dose, Post-dose on Days 2, 3, 5,11, 15 and 29 of Cycle 6; Pre-dose was taken 2 hours prior rituximab dose
Reported as:
Number · mg
Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab
mgPart 1: Rituximab SC
Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab1600
PrimaryPart 2: Rituximab C Trough Levels at Cycle 5

Ctrough is defined as the trough or minimum serum concentration in a given cycle of treatment. The objective of Part 2 was to demonstrate the comparability of the observed Ctrough of rituximab SC 1600 mg and rituximab IV 500 mg/m2 at Cycle 5, as assessed by a non-inferiority test with a lower boundary of at least 0.8 for the 90% CI.

Time frame:
+/- 25hours around the 28th day post the 5th Cycle of Rituximab administration
Reported as:
Geometric mean · μg/mL
Part 2: Rituximab C Trough Levels at Cycle 5
μg/mLPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Part 2: Rituximab C Trough Levels at Cycle 561.50 ± 89.5497.53 ± 55.27
Statistical analysis
  • Part 2 : Rituximab IV 500 mg/m^2 vs Part 2: Rituximab SC 1600 mg · Adjusted geometric mean ratio: 1.533 · 90% CI 1.269 to 1.852Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.
SecondaryPart 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6

AUC values were calculated by numerical integration using the linear trapezoidal rule. AUC levels were analyzed using the model below: Ln(AUC) = μ + τi + BlTLij + εij wherein, Ln is the natural log, μ denotes the overall mean effect, τi the effect in each treatment group, BlTLij the tumor load at baseline for each patient and εij a random error variable with normal distribution and mean 0. The treatment effect therein was based on a contrast statement in the model to calculate 90 % confidence intervals for ln(AUC SC)- ln(AUC IV).

Time frame:
Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Reported as:
Geometric mean · μg*day/mL
Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6
μg*day/mLPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 63630.43 ± 38.614088.78 ± 37.52
Statistical analysis
  • Part 2 : Rituximab IV 500 mg/m^2 vs Part 2: Rituximab SC 1600 mg · Adjusted geometric mean ratio: 1.102 · 90% CI 0.979 to 1.242Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.
SecondaryPart 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6

Cmax was obtained directly from the measured concentration-time curves. The concentration-time curve is the result of time points of blood sampling and its measured concentration of rituximab in the blood samplings.

Time frame:
Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Reported as:
Geometric mean · μg/mL
Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6
μg/mLPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6279.78 ± 23.96202.16 ± 36.10
Statistical analysis
  • Part 2 : Rituximab IV 500 mg/m^2 vs Part 2: Rituximab SC 1600 mg · Adjusted geometric mean ratio: 0.719 · 90% CI 0.653 to 0.792Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.
SecondaryPart 2: Time to Cmax (Tmax) of Rituximab at Cycle 6

Multiple blood samples were obtained at pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab IV arm, and at pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6 in Rituximab SC arm and time to peak plasma concentration of rituximab was determined.

Time frame:
Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Reported as:
Geometric mean · days
Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6
daysPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 60.22 ± 130.843.14 ± 87.62
Statistical analysis
  • Part 2 : Rituximab IV 500 mg/m^2 vs Part 2: Rituximab SC 1600 mg · Adjusted geometric mean ratio: 14.884 · 90% CI 11.215 to 19.755Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.
SecondaryPart 2: Terminal Half-Life of Rituximab at Cycle 6

The terminal half-life (t1/2) of rituximab is defined as the time required for the plasma concentration of rituximab to reach half of its original concentration.

Time frame:
Rituximab IV arm: pre-dose, post-dose and on Days 2, 3, 8 ,15, 29 of Cycle 6; Rituximab SC arm: pre-dose, and on Days 2, 3, 8 ,15, 29 of Cycle 6
Reported as:
Geometric mean · days
Part 2: Terminal Half-Life of Rituximab at Cycle 6
daysPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Part 2: Terminal Half-Life of Rituximab at Cycle 630.09 ± 41.8630.71 ± 33.19
Statistical analysis
  • Part 2 : Rituximab IV 500 mg/m^2 vs Part 2: Rituximab SC 1600 mg · Adjusted geometric mean ratio: 1.010 · 90% CI 0.895 to 1.139Ratio based on geometric scale and adjusted for the covariate tumor load at baseline.
SecondaryPart 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration

In part 1 of the trial, upon completion of dosing in cycle 6, participants and their treating nurses were asked whether they have a preference of dosing route, IV vs SC

Time frame:
Days 4 to 5 in Cycle 6
Reported as:
Number · percentage of participants or nurses
Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration
percentage of participants or nursesPart 1: Rituximab SC 1400 mgPart 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mg
Participants who preferred SC88.0100.091.0
Participants who preferred IV13.00.09.0
Nurses who preferred SC88.0100.091.0
Nurses who preferred IV13.00.09.0
SecondaryPart 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV

Physicians and nurses who administered rituximab were asked to answer the following question: " If used in routine practice, on average, how much staff time could be saved with each administration of rituximab SC as compared to rituximab IV? (Please do not consider the time needed for the first IV administration, consider only the subsequent ones)". The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.

Time frame:
Days 4-5 in Cycle 6
Reported as:
Number · percentage of participants in the survey
Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV
percentage of participants in the surveyPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Nurse: 4 or more hours21.021.0
Nurse: At least 3 hours but less than 4 hours23.029.0
Nurse: At least 2 hours but less than 3 hours26.023.0
Nurse: At least 1 hour but less than 2 hours17.011.0
Nurse: Less than 1 hour13.016.0
Physician: 4 or more hours21.022.0
Physician: At least 3 hours but less than 4 hours18.021.0
Physician: At least 2 hours but less than 3 hours24.026.0
Physician: At least 1 hour but less than 2 hours22.019.0
Physician: Less than 1 hour10.07.0
SecondaryPart 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV

Physicians and nurses who administered rituximab were asked to answer the following question: "Which formulation of rituximab (SC or IV) do you think is more convenient?" with pre-specified responses as below. Percentage of participants with specified answers were reported. The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.

Time frame:
Days 4-5 in Cycle 6
Reported as:
Number · percentage of participants in the survey
Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV
percentage of participants in the surveyPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Nurse: Rituximab SC is much more convenient81.077.0
Nurse: Rituximab SC is a little more convenient7.09.0
Nurse: Both formulations are equally convenient9.04.0
Nurse: Rituximab IV is a little more convenient3.010.0
Nurse: Rituximab IV is much more convenient0.00.0
Physician: Rituximab SC is much more convenient78.080.0
Physician: Rituximab SC a little more convenient15.014.0
Physician: Both formulations equally convenient6.06.0
Physician: Rituximab IV a little more convenient0.00.0
Physician: Rituximab IV is much more convenient0.00.0
SecondaryPart 1: Percentage of Participants With Anti-Rituximab Antibodies

Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.

Time frame:
Predose at Cycles 5 and 6 and at each follow up visit until 24 months after the last dose
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Anti-Rituximab Antibodies
percentage of participantsPart 1: Rituximab SC
Pre-Dose Cycle 5: positive for HACAs (n=59)0.0
Pre-Dose Cycle 5: negative for HACAs (n=59)100.0
Post-Dose: positive for HACAs (n=61)5.0
Post-Dose: negative for HACAs (n=61)95.1
SecondaryPart 2: Percentage of Participants With Anti-Rituximab Antibodies

In Part 2, samples for the HACA assay were collected at each treatment cycle prior to the administration of rituximab and at each follow-up visit until 24 months after the last dose of rituximab.

Time frame:
Day 0 of Cycle 1 and Day 1 of Cycles 1, 2, 3, 4, 5, and 6 and at each follow-up visit until 24 months after the last dose of rituximab.
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Anti-Rituximab Antibodies
percentage of participantsPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Baseline pre Cycle 1: positive for HACAs (n=87,85)0.02.4
Baseline pre Cycle 1: negative for HACAs (n=87,85)100.097.6
Post-Baseline: positive for HACAs (n=89,85)15.012.0
Post-Baseline: negative for HACAs (n=89,85)85.088.0
SecondaryPart 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit

CD 19 is a surface antigen (protein) present on B-lymphocytes.

Time frame:
Day 1 of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15,18, 21 and 24
Reported as:
Median · cells per microliter (cells/μL)
Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit
cells per microliter (cells/μL)Part 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: Rituximab SC 1000 mgPart 1: No SC Dose Received
Cycle 5 Day 1 (n=15,13,19,1,2)2 (0 to 157)3 (0 to 419)0 (0 to 19)84 (NA to NA)2 (1 to 2)
Cycle 6 Day 1 (n=15,14,18,1,0)1 (0 to 90)2 (0 to 22)1 (0 to 5)27 (NA to NA)NA (NA to NA)
FU 28 Day Visit (n=15,11,19,1,0)2 (0 to 113)2 (0 to 8)0 (0 to 7)7 (NA to NA)NA (NA to NA)
FU 56 Day Visit (n=15,9,15,1,0)1 (0 to 215)3 (1 to 42)0 (0 to 2)14 (NA to NA)NA (NA to NA)
FU 3 Month Visit (n=16,8,18,0,0)3 (0 to 469)1 (0 to 5)1 (0 to 6)NA (NA to NA)NA (NA to NA)
FU 6 Month Visit (n=15,13,17,1,0)2 (0 to 5929)1 (0 to 265)2 (0 to 96)51 (NA to NA)NA (NA to NA)
FU 9 Month Visit (n=15,13,15,1,0)66 (0 to 15727)19 (1 to 728)29 (0 to 1153)74 (NA to NA)NA (NA to NA)
FU 12 Month Visit (n=14,14,20,0,0)126 (4 to 1457)31 (0 to 2775)90 (2 to 1281)NA (NA to NA)NA (NA to NA)
FU 15 Month Visit (n=14,11,15,0,0)175 (14 to 2426)41 (3 to 6588)106 (29 to 500)NA (NA to NA)NA (NA to NA)
FU 18 Month Visit (n=13,14,15,0,0)175 (15 to 5871)82 (16 to 13749)189 (22 to 478)NA (NA to NA)NA (NA to NA)
FU 21 Month Visit (n=13,12,16,0,0)128 (27 to 10679)78 (9 to 314)149 (57 to 783)NA (NA to NA)NA (NA to NA)
FU 24 Month Visit(n=12, 4,16,0,0)238 (29 to 11989)110 (25 to 2225)232 (69 to 1343)NA (NA to NA)NA (NA to NA)
SecondaryPart 1: Percentage of Participants With Total B-Cell Depletion by Visit

Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.

Time frame:
Day 1 pre-dose of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15, 18, 21 and 24
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Total B-Cell Depletion by Visit
percentage of participantsPart 1: Rituximab SC 1400 mgPart 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgRituximab SC 1000 mgPart 1: No SC Dose Received
Cycle 5 Day 1 (n=15,1319,1,2)93.392.3100.00.0100.0
Cycle 6 Day 1(n= 15,14,18,1,0)93.3100.0100.0100.0NA
FU 28 Day Visit (n=15,11,19,1,0)93.3100.0100.0100.0NA
FU 56 Day Visit (n=15,9,15,1,0)93.3100.0100.0100.0NA
FU 3 Month Visit (n=16,8,18,0,0)93.8100.0100.0NANA
FU 6 Month Visit (n=15,13,17,1,0)86.792.394.1100.0NA
FU 9 Month Visit (n=15,13,15,1,0)53.384.660.0100.0NA
FU 12 Month Visit (n=14,14,20,0,0)28.685.745.0NANA
FU 15 Month Visit (n=14,11,15,0,0)35.754.540.0NANA
FU 18 Month Visit (n=13,14,15,0,0)30.850.026.7NANA
FU 21 Month Visit (n=13,12,16,0,0)30.850.018.8NANA
FU 24 Month Visit (n=12,14,16,0,0)25.021.418.8NANA
SecondaryPart 2: Total CD19+ B-Cell Counts by Visit

CD 19 is a surface antigen (protein) present on B-lymphocytes.

Time frame:
Cycle 1 pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 pre-dose in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit
Reported as:
Median · cells/μL
Part 2: Total CD19+ B-Cell Counts by Visit
cells/μLPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Cycle 1 - Baseline (n=80,80)68905 (3996 to 277645)50565 (640 to 453292)
Cycle 2 - Pre-dose (n=71,74)338 (2 to 38252)253 (1 to 92469)
Cycle 2 - Post-dose (n=65, 66)163 (3 to 13026)168 (1 to 32615)
Cycle 2 Day 2 (n=54, 59)154 (6 to 10416)266 (0 to 40815)
Cycle 2 Day 3 (n=48, 54)87 (0 to 14769)125 (0 to 13229)
Cycle 3 Day 1 (n=67,68)12 (0 to 13118)8 (1 to 22392)
Cycle 4 Day 1 (n=71,69)4 (0 to 17827)4 (0 to 18672)
Cycle 5 Day 1 (n=68,67)2 (0 to 7146)2 (0 to 8542)
Cycle 6 Day 1 (n=71,64)3 (0 to 3612)3 (0 to 4234)
FU 28 Day Visit (n=66,64)2 (0 to 1299)2 (0 to 2749)
FU 56 Day Visit (n=63,67)2 (0 to 14331)2 (0 to 3539)
FU 3 Month Visit (n=67,67)2 (0 to 39037)2 (0 to 16413)
FU 6 Month Visit (n=60,69)3 (0 to 1356)3 (0 to 22630)
FU 9 Month Visit (n=65,64)35 (1 to 3776)30 (0 to 890)
FU 12 Month Visit (n=60,61)91 (4 to 9372)104 (1 to 1770)
FU 15 Month Visit (n=59,60)135 (6 to 16328)171 (5 to 9431)
FU 18 Month Visit (n=57,58)134 (5 to 15404)223 (3 to 22363)
FU 21 Month Visit (n=55,52)171 (5 to 7901)277 (5 to 39435)
FU 24 Month Visit (n=56,51)214 (0 to 78010)256 (6 to 10482)
Withdrawn/Termination (n=17,15)150 (2 to 90310)6 (0 to 35325)
SecondaryPart 2: Percentage of Participants With Total B-Cell Depletion by Visit

Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.

Time frame:
Cycle 1 Pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Total B-Cell Depletion by Visit
percentage of participantsPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Cycle 1 - Baseline (n=80,80))0.00.0
Cycle 2 - Pre-dose (n=71, 74)23.931.1
Cycle 2 - Post-dose (n=65, 66)32.337.9
Cycle 2 Day 2 (n=54, 59)35.230.5
Cycle 2 Day 3 (n=48, 54)50.037.0
Cycle 3 Day 1 (n=67,68)73.176.5
Cycle 4 Day 1 (n=71,69)83.184.1
Cycle 5 Day 1 (n=68,67)88.289.6
Cycle 6 Day 1 (n=71,64)95.895.3
FU 28 Day Visit (n=66,64)95.596.9
FU 56 Day Visit (n=63,67)92.197.0
FU 3 Month Visit (n=67,67)95.592.5
FU 6 Month Visit (n=60,69)88.391.3
FU 9 Month Visit (n=65,64)66.270.3
FU 12 Month Visit (n=60,61)43.342.6
FU 15 Month Visit (n=59,60)33.930.0
FU 18 Month Visit (n=57,58)24.625.9
FU 21 Month Visit (n=55,52)14.519.2
FU 24 Month Visit (n=56,51)10.715.7
Withdrawn/Termination (n=17,15)41.273.3

Adverse events

Collected over Adverse Events were recorded from the time of initiation of treatment until 28 days after completion of study treatment in Cycle 6.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Rituximab SC 1400 mg—5/16 (31.3%)13/16 (81.3%)
Part 1: Rituximab SC 1600 mg—8/17 (47.1%)16/17 (94.1%)
Part 1: Rituximab SC 1870 mg—4/22 (18.2%)21/22 (95.5%)
Part 1: Rituximab SC 1000 mg—1/1 (100%)1/1 (100%)
Part 1: No SC Dose Received—3/8 (37.5%)7/8 (87.5%)
Part 2 : Rituximab IV 500 mg/m^2—35/89 (39.3%)80/89 (89.9%)
Part 2: Rituximab SC 1600 mg—32/85 (37.6%)81/85 (95.3%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventPart 1: Rituximab SC 1400 mgPart 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: Rituximab SC 1000 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
Febrile NeutropeniaBlood and lymphatic system disorders0/161/172/221/11/84/899/85
Bone Marrow FailureBlood and lymphatic system disorders0/160/170/221/10/80/890/85
ENTEROCOLITISGastrointestinal disorders0/160/170/221/10/80/890/85
BACTERIAL SEPSISInfections and infestations0/160/170/221/10/80/890/85
BRONCHITISInfections and infestations0/160/170/221/10/80/890/85
AnaemiaBlood and lymphatic system disorders0/160/170/220/11/83/890/85
PeumoniaInfections and infestations1/161/171/220/11/83/892/85
PyrexiaGeneral disorders0/161/170/220/11/81/893/85
HypersensitivityImmune system disorders0/160/170/220/11/80/890/85
Tumor Lysis SyndromeMetabolism and nutrition disorders0/160/170/220/11/80/890/85
Most frequent other events
Showing 10 of 106
Most frequent other events
EventPart 1: Rituximab SC 1400 mgPart 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 1: Rituximab SC 1000 mgPart 1: No SC Dose ReceivedPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mg
NeutropeniaBlood and lymphatic system disorders7/168/179/221/13/851/8954/85
AnaemiaBlood and lymphatic system disorders2/162/171/221/12/821/8911/85
ThrombocytopeniaBlood and lymphatic system disorders0/163/172/221/11/825/8920/85
NauseaGastrointestinal disorders2/166/174/220/12/831/8932/85
LeukopeniaBlood and lymphatic system disorders3/166/170/220/11/815/8916/85
VomitingGastrointestinal disorders2/162/177/220/12/820/8918/85
PyrexiaGeneral disorders1/165/171/220/11/823/8926/85
Injection site erythemaGeneral disorders0/162/174/220/10/80/8922/85
DiarrhoeaGastrointestinal disorders1/164/173/220/11/89/8910/85
SinusitisInfections and infestations0/162/174/220/10/85/893/85

Baseline characteristics

Safety Analysis Population (SAP): all participants who received at least one dose of study medication whether prematurely withdrawn or not. In Part 2 two participants randomized to the rituximab SC 1600 mg arm were included in Rituximab IV 500 mg/m\^2 arm as they received only the first cycle of rituximab IV 375 mg/m\^2.

Age, Continuous
Age, Continuous(years)Part 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mgTotal
Mean56.6 ± 10.1360.4 ± 8.1856.9 ± 6.7958.7 ± 9.0359.1 ± 8.8758.8 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Rituximab SC 1400 Milligrams (mg)Part 1: Rituximab SC 1600 mgPart 1: Rituximab SC 1870 mgPart 2 : Rituximab IV 500 mg/m^2Part 2: Rituximab SC 1600 mgTotal
Female627362576
Male1015155360153
08

Study locations

84 sites
  • Fundaleu; Haematology
    Buenos Aires, C1114AAN, Argentina
  • Cemic; Haematology
    Buenos Aires, C1431FWO, Argentina
  • HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología
    Córdoba, 5016, Argentina
  • St George Hospital; Department of Haematology
    Kogarah, New South Wales 2217, Australia
  • Royal Brisbane and Women'S Hospital; Haematology
    Herston, Queensland 4029, Australia
  • Ashford Cancer Center Research
    Kurralta Park, South Australia 5037, Australia
  • Queen Elizabeth Hospital; Haematology
    Woodville South, South Australia 5011, Australia
  • St Vincent'S Hospital; Haematology
    Fitzroy, Victoria 3065, Australia
  • Frankston Hospital; Oncology/Haematology
    Frankston, Victoria 3199, Australia
  • Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia
    Passo Fundo, RS 99010-260, Brazil
  • Hospital Mae de Deus
    Porto Alegre, RS 90470-340, Brazil
  • Hospital Sirio Libanes; Centro de Oncologia
    Sao Paulo, SP 01308-050, Brazil
  • Hospital das Clinicas - FMUSP
    Sao Paulo, SP 05403-000, Brazil
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
    Montreal, Quebec H3T 1E2, Canada
  • Centre de sante et de services sociaux Rimouski Neigette
    Rimouski, Quebec G5L 5T1, Canada
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
  • Instituto Nacional del Cancer
    Santiago, 8380000, Chile
  • Centro Internacional de Estudios Clínicos (CIEC)
    Santiago, 8420383, Chile
  • Clinical Hospital Merkur; Dept of Haematology
    Zagreb, 10000, Croatia
  • University Hospital Center Zagreb; Haematology Department
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • University Hospital and Medical School; IV.Dept. of Internal Medicine and Hematology
    Hradec Kralove, 500 05, Czechia
  • Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
    Praha 2, 128 08, Czechia
  • Centre Francois Baclesse
    Caen, 14076, France
  • Institut J Paolii Calmettes; Onco Hematologie 1
    Marseille, 13273, France
  • Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)
    Paris, 75475, France
  • Hopital Robert Debre; Hematologie Clinique
    Reims, 51092, France
  • Hopitaux De Brabois; Hematologie Medecine Interne
    Vandoeuvre Les Nancy, 54511, France
  • Onkologische Schwerpunktpraxis Kurfürstendamm
    Berlin, 10707, Germany
  • Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch
    Berlin, 14195, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Klinikum Frankfurt; Medizinische Klinik I
    Frankfurt an der Oder, 15236, Germany
  • Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
    Greifswald, 17475, Germany
  • Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w.
    Hannover, 30171, Germany
  • Gemeinschaftspraxis Dr. Siehl & Dr. Soeling
    Kassel, 34119, Germany
  • Klinik der Uni zu Köln; Klinik für Innere Medizin
    Köln, 50924, Germany
  • K&K Studien GbR
    Landshut, 84028, Germany
  • Onkologische Schwerpunktpraxis Lübeck
    Lübeck, 23562, Germany
  • Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach
    Marburg, 35037, Germany
  • Klinikum Grosshadern der LMU
    Muenchen, 81377, Germany
  • Medizinisches Versorgungszentrum MOP
    München, 80335, Germany
  • Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura
    Neunkirchen/Saar, 66538, Germany
  • Prosper-Hospital, Medizinische Klinik I
    Recklinghausen, 45659, Germany
  • Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine
    Athens, 115 27, Greece
  • Papageorgiou General Hospital of Thessaloniki; Hematology Clinic
    Thessaloniki, 54629, Greece
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
    Meldola, Emilia-Romagna 47014, Italy
  • Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia
    Ravenna, Emilia-Romagna 48100, Italy
  • Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia
    Rimini, Emilia-Romagna 47900, Italy
  • A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo
    Milano, Lombardia 20132, Italy
  • ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia
    Milano, Lombardia 20162, Italy
  • Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
    Novara, Piemonte 28100, Italy
  • Policlinico G. B. Rossi; Divisione Di Ematologia
    Verona, Veneto 37134, Italy
  • Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre
    Chihuahua, 31000, Mexico
  • Hospital General De Culiacan; Servicio De Hematologia
    Culiacan, 80230, Mexico
  • Hospital Universitario Dr. Jose E. Gonzalez; Haematology
    Monterrey, 64460, Mexico
  • Canterbury Health Laboratories; Haematology
    Christchurch, 8011, New Zealand
  • Wellington Hospital; Wellington Blood and Cancer Centre
    Newtown, 6021, New Zealand
  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
    Gdansk, 80-952, Poland
  • Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie
    Lublin, 20-081, Poland
  • Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Lymphoma Dept.
    Warszawa, 02-781, Poland
  • Medical Uni of Wroclaw; Hematology
    Wroclaw, 50-367, Poland
  • Hospital de Santa Maria; Servico de Hematologia e Transplantacao de Medula
    Lisboa, 1600, Portugal
  • IPO do Porto; Servico de Onco-Hematologia
    Porto, 4200-072, Portugal
  • N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis
    Moscow, 115478, Russian Federation
  • City Clinical Hospital After Botkin; Hematology
    Moscow, 125101, Russian Federation
  • Haematology Research Center; Haematology
    Moscow, 125167, Russian Federation
  • Penza Regional Oncology Dispensary
    Penza, 440071, Russian Federation
  • Clinical MSCh No1
    Perm, 614077, Russian Federation
  • St. Petersburg State Medical University n.a. I.P. Pavlov; Hematology, transfusiology and transplanta
    Saint-Petersburg, 197022, Russian Federation
  • National Oncology Inst. ; Dept. of Haematology
    Bratislava, 833 10, Slovakia
  • University Hospital; Clinic of Hematology & Transfusiology
    Bratislava, 851 07, Slovakia
  • Hospital Universitari Vall d'Hebron; Servicio de Hematologia
    Barcelona, 08035, Spain
  • Hospital Universitario de la Princesa; Servicio de Hematologia
    Madrid, 28006, Spain
  • Hospital Universitario Puerta de Hierro; Servicio de Hematologia
    Madrid, 28222, Spain
  • Hospital Clinico Universitario de Salamanca;Servicio de Hematologia
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Hematología
    Toledo, 45004, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Hacettepe Uni Medical Faculty; Hematology
    Ankara, 06100, Turkey
  • Istanbul University Cerrahpasa Medical Faculty; Hematology Department
    Istanbul, 34098, Turkey
  • Dokuz Eylul Uni ; Hematology
    Izmir, 35100, Turkey
  • Ege University ARGEFAR
    Izmir, 35100, Turkey
09

References and documents

Publications

  • Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, Brewster M, Catalani O, Li S, McIntyre C, Sayyed P, Badoux X. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016 Mar;3(3):e128-38. doi: 10.1016/S2352-3026(16)00004-1. PubMed 26947201 ↗
  • Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, Catalani O, Hourcade-Potelleret F, Sayyed P, Badoux X. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015 Nov;80(5):1001-9. doi: 10.1111/bcp.12662. Epub 2015 Jul 29. PubMed 25900065 ↗
  • Mao CP, Brovarney MR, Dabbagh K, Birnbock HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One. 2013 Nov 12;8(11):e80533. doi: 10.1371/journal.pone.0080533. eCollection 2013. PubMed 24265828 ↗
  • Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013 Sep 17;109(6):1556-61. doi: 10.1038/bjc.2013.371. Epub 2013 Sep 3. PubMed 24002601 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in May 2014, 36 months.

Results were first posted in Dec 2015, 1 year 7 months after primary completion.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 36 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2011
First posted
Feb 9, 2011
StartActual
Apr 18, 2011
Primary completionActual
May 7, 2014
CompletionActual
Nov 17, 2017
Results first posted
Dec 15, 2015
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01292603
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 9, 2011
Start date
Apr 18, 2011
Primary completion
May 7, 2014
Completion
Nov 17, 2017
Results posted
Dec 15, 2015
Last update
Dec 19, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine

Start the discussion